8-K current report · filed Aug 6, 2026

COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K Current Report: August 6, 2026

Item 2.02Item 7.01Item EX-99.1COLL overview

Short answer

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Quarterly results announced for the period ended June 30, 2026.

COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Quarterly results announced for the period ended June 30, 2026
  • Full financial results and management commentary provided in Exhibit 99.1
  • Results announcement dated August 6, 2026, giving investors the company’s latest operating update

Item 7.01 · Regulation FD Disclosure

  • Earnings presentation released August 6, 2026
  • Exhibit 99.2 contains management’s earnings-related investor materials
  • Presentation may provide additional operating and financial context beyond the 8-K text

Item EX-99.1 · Exhibit EX-99.1

  • Q2 product revenue $199.9M, up 6% YoY; JORNAY PM revenue $46.1M, up 41%, supporting ADHD growth thesis
  • AZSTARYS acquisition contributed $12.9M from May 12 and lifted full-year guidance to $65–$75M
  • Pain revenue fell 9% to $140.9M, with Nucynta down 24% and Xtampza down 14%, offsetting ADHD momentum
  • Full-year product revenue guidance reduced to $825–$855M and adjusted EBITDA to $445–$470M, primarily from weaker Nucynta authorized-generic pricing
  • GAAP net loss $15.1M versus $12.0M income; adjusted EBITDA rose 8% to $113.8M, while acquisition costs increased operating expenses 45% to $106.6M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings

Get the next COLL 8-K as it lands

Follow COLL for push alerts, or ask the research agent what this filing means.